Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Clasificación en acciones #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Precio por acción
$0.0327
Última sincronización: 2025-06-17
Capitalización bursátil
$4.34M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
IL
Comercio Gamida Cell Ltd. (GMDA)

Categoría

Historial de desdoblamientos de acciones de Gamida Cell Ltd. (GMDA)
La acción Gamida Cell Ltd. (símbolo: GMDA) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 16, 2026.
Una acción GMDA comprada antes de Aug 16, 2026 equivaldría hoy a 0 acciones GMDA.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE